1.
Eur Rev Med Pharmacol Sci
; 25(5): 2313-2317, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33755968
RESUMO
Adoptive CAR T cell therapy (chimeric antigen receptor T-Cell) has received increasing attention in recent years; however, its efficacy is undesirable and differs from person to person. Understanding how to overcome this obstacle is important to improve therapy. Infusion of poorly differentiated CAR-CD62L+ T cells, such as T memory stem cell populations, leads to enhanced T cell implantation, expansion, and persistence, which ultimately leads to more stable tumour regression. Here, we reviewed emerging findings demonstrating that CAR structure and cell culture conditions can influence CAR T cell differentiation and antitumour efficacy.